Research programme: asthma therapeutics - Targepeutics
Alternative Names: TARG-ALLERG 1-200; TARG-ALLERG 1-201; TARG-ALLERG 1-202Latest Information Update: 18 Jan 2011
Price :
$50 *
At a glance
- Originator Targepeutics
- Class
- Mechanism of Action Interleukin 13 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Allergic asthma
Most Recent Events
- 05 Sep 2005 Potential therpaeutics from this programme are available for licensing (http://www.targepeutics.com)
- 05 Sep 2005 Preclinical trials in Allergic asthma in USA (Inhalation)